Interim biomarker results for trontinemab, a novel Brainshuttle™ antibody in development for the treatment of Alzheimer’s disease

Abstract

Background: Trontinemab is a novel amyloid‐targeting Brainshuttle™ monoclonal antibody specifically engineered for efficient transferrin receptor 1‐mediated transport across the blood–brain barrier.

The paper